Combatting Malicious Tampering in Pharma: The Weakspots



We respect your privacy, by clicking "Download Your Copy" you will receive our e-newsletter, including information on Podcasts, Webinars, event discounts, online learning opportunities and agree to our User Agreement. You have the right to object . In addition, you agree to having your details passed onto the sponsor who may promote similar products and services related to your area of interest subject to their privacy policy. For further information on how we process and monitor your personal data click here. You can unsubscribe at any time.

Counterfeit pharmaceuticals can cause a lot of harm – drug recalls, loss of public confidence, law suits, and risks to patient safety. In the combat against malicious tampering, anti-counterfeiting technology aims to prevent the emergence of counterfeit drugs by creating hurdles to deter by making the task of cloning a drug too complex and expensive.

The size of the anti-counterfeit, anti-tampering and authentication packaging market is forecasted to expand by a CAGR of 14.1% to 2019. However, the anti-tampering market has experienced a lot of hurdles to tackle. Numerous challenges are encountered when assessing how to adhere to EU FMD requirements. Pharmaceutical companies need to define, specify, test and choose the tamper verification feature for their existing and future packaging portfolio. Considerations especially need to be applied for how individual products are affected by country specific requirements. This infographic assesses the top weaknesses experienced within pharmaceutical packaging and labelling. (4)

[inlinead]

Areas covered in this whitepaper include: 

Folding Boxes:

- Labelling

- Stability

Bottles:

- Induction cup sealing technology

Production and Anti-Tamper feature of choice: 

- Common Weaknesses

Download your complimentary copy below. 

Have Your Say
Rate this feature and give us your feedback in the comments section below

RECOMMENDED